Blocking this interaction via anti-PD-1 or anti-PD-L1 monoclonal antibodies restores the T cell from its “exhausted” phenotype, improves local T cells proliferation and effector function, and ultimately results in anti-tumor immunity (34). The gene discussed is CD274; the disease is neoplasm.